Europe Enzyme Replacement Therapy Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Enzyme Type (Alglucosidase Alfa, Agalsidase Beta, Imiglucerase, Idursulfase, Galsulfase, Velaglucerase Alfa, and Other Enzymes), Therapeutic Conditions (Gaucher's Disease, Fabry's Disease, MPS, Pompe's Disease, SCID, and Other Therapeutic Conditions), Route of Administration (Parenteral and Oral), and End User (Hospitals, Infusion Centers, and Others)
The enzyme replacement therapy market in Europe is expected to grow from US$ 2,900.09 million in 2022 to US$ 4,206.54 million by 2028; it is estimated to grow at a CAGR of 6.4% from 2022 to 2028.
Rapid Regulatory Approval with Other Benefits for Drugs with Orphan Drug Designation
A condition that affects fewer than 200,000 people nationwide is termed as orphan disease. Fabry's disease, Pompe disease, and Hunter syndrome are among a few examples. European Medicines Agency (EMA) deals with approving orphan drugs. For instance, according to EMA, if a product that has an orphan drug designation receives EMA marketing approval for the indication, the product is entitled to orphan market exclusivity; this means the EMA may not approve any other application to market a similar drug for the same indication for 10 years. Furthermore, in March 2016, the EMA launched the Priority Medicines ("PRIME") scheme to facilitate the development of product candidates in indications for which few or no therapies currently exist. The PRIME scheme also provides several benefits to drug producers once a candidate medicine is selected. Below mentioned are the benefits provided by the EMA:
• Appoints a rapporteur from the Committee for Medicinal Products for Human Use (CHMP) and help to build knowledge ahead of a marketing-authorization application
• Early and proactive regulatory dialogue with the EMA to guide the overall development plan and regulatory strategy
• Offers scientific advice at key development milestones, involving additional stakeholders, such as health-technology-assessment bodies, to facilitate quicker access for patients to the new medicine
• Confirms potential for accelerated assessment at the time of an application for marketing authorization
Therefore, owing to the benefit and incentives associated with drugs designated as orphan drugs, key players operating in the market are putting efforts into developing drugs for orphan diseases. For instance, Amicus Therapeutics, Inc. recently obtained an orphan medicinal product designation in Europe from the EMA for Galafold to treat Fabry disease and the combination product—ATB200/AT2221—for treating Pompe disease. Additionally, in September 2020, Amicus Therapeutics, Inc. was granted PRIME designation for AT-GTX-501 for the treatment of CLN6 or Batten disease. Thus, the rapid regulatory approval with other marketing benefits for the drug with orphan drug designation is driving the market growth.
Market Overview
The Europe enzyme replacement therapy market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany is considered among the fastest-growing enzyme replacement therapy markets in Europe. The growing importance of enzyme replacement therapy is due to rising healthcare expenditure, which is aiding the market growth in Germany. The federal statistical office reported an increase in the health expenditure in Germany, which aids in research and development in the healthcare sector. For instance, in April 2022, the Federal Statistical Office (Destatis) confirmed that health spending in 2020 was 26.8 billion euros, or 6.5% higher than in 2019. Moreover, according to German Trade and Invest (GTAI), on average, more than 710 companies are engaged in the biotechnology sector. Germany has experienced a boom in innovative pharmaceutical companies, drug manufacturers, contract research organizations (CROs), and small-medium-sized biopharmaceutical companies over the years. In February 2020, as per the paper “Developments in the treatment of Fabry disease” published in Wiley Online Library, a new form of ERT- moss-aGal, for the treatment of Fabry Disease (FD) was developed by Greenovation biopharmaceuticals, in Germany. Moreover, the rising government health expenditure and increasing biotechnology and pharmaceutical companies are boosting the enzyme replacement therapy market, which is also boosting the growth of the Europe enzyme replacement therapy market.
Europe Enzyme Replacement Therapy Market Revenue and Forecast to 2028 (US$ Million)
Get more information on this report :
Europe Enzyme Replacement Therapy Market Segmentation
The Europe enzyme replacement therapy market is segmented into enzyme type, therapeutic conditions, route of administration, end user, and country.
- Based on enzyme type, the market is segmented into alglucosidase alfa, agalsidase beta, imiglucerase, idursulfase, galsulfase, velaglucerase alfa, and other enzymes. The other enzymes segment registered the largest market share in 2022.
By therapeutic conditions, the market is segmented into Gaucher's disease, Fabry's disease, MPS, Pompe's disease, SCID, and other therapeutic conditions. The Gaucher's disease segment held the largest market share in 2022.
In terms of route of administration, the market is bifurcated into parenteral and oral. The parenteral segment held a larger market share in 2022.
From end user point of reference, the market is segmented into hospitals, infusion centers, and others. The hospitals segment held the largest market share in 2022.
- Based on country, the market is segmented into Germany, the UK, France, Italy, Spain, rest of Europe. Germany dominated the market in 2022.
Sanofi; BioMarine Pharmaceutical Inc; Takeda Pharmaceutical Company Limited; AbbVie Inc; Janssen Pharmaceutical (Johnson & Johnson Services, Inc.); Alexion Pharmaceutical, Inc. (AstaZeneca); Amicus Therapeutics; Recordati S.p.A; Recordati S.p.A; CHIESI farmaceutici S.p.A; and Pfizer Inc are the leading companies operating in the enzyme replacement therapy market in Europe.
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Europe Enzyme Replacement Therapy Market – By Enzyme Type
1.3.2 Europe Enzyme Replacement Therapy Market – By Therapeutic Conditions
1.3.3 Europe Enzyme Replacement Therapy Market – By Route of Administration
1.3.4 Europe Enzyme Replacement Therapy Market – By End User
1.3.5 Europe Enzyme Replacement Therapy Market – By Country
2. Europe Enzyme Replacement Therapy Market– Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Enzyme Replacement Therapy Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Europe – PEST Analysis
4.3 Expert Opinion
5. Europe Enzyme Replacement Therapy Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of Lysosomal Storage Diseases (LSDs)
5.1.2 Rapid Regulatory Approval with Other Benefits for Drug with Orphan Drug Designation
5.2 Market Restraints
5.2.1 Cutthroat Competition among Market Players
5.3 Market Opportunities
5.3.1 Increasing Partnerships and Collaborations to Synergize the Business
5.4 Future Trends
5.4.1 Innovative Developments in ERT
5.5 Impact Analysis
6. Enzyme Replacement Therapy Market– Europe Analysis
6.1 Europe Enzyme Replacement Therapy Market Revenue Forecast and Analysis
7. Europe Enzyme Replacement Therapy Market Revenue and Forecasts To 2028– by Enzyme Type
7.1 Overview
7.2 Europe Enzyme Replacement Therapy Market, By Enzyme Type 2021 & 2028 (%)
7.3 Alglucosidase Alfa
7.3.1 Overview
7.3.2 Alglucosidase Alfa Revenue and Forecast to 2028 (US$ Million)
7.4 Agalsidase Beta
7.4.1 Overview
7.4.2 Agalsidase Beta - Revenue and Forecast to 2028 (US$ Million)
7.5 Imiglucerase
7.5.1 Overview
7.5.2 Imigluceras - Revenue and Forecast to 2028 (US$ Million)
7.6 Idursulfase
7.6.1 Overview
7.6.2 Idursulfase - Revenue and Forecast to 2028 (US$ Million)
7.7 Galsulfase
7.7.1 Overview
7.7.2 Galsulfase - Revenue and Forecast to 2028 (US$ Million)
7.8 Velaglucerase Alfa
7.8.1 Overview
7.8.2 Velaglucerase Alfa - Revenue and Forecast to 2028 (US$ Million)
7.9 Other Enzymes
7.9.1 Overview
7.9.2 Other Enzymes - Revenue and Forecast to 2028 (US$ Million)
8. Europe Enzyme Replacement Therapy Market Analysis and Forecasts To 2028 – By Therapeutic Conditions
8.1 Overview
8.2 Europe Enzyme Replacement Therapy Market, By Therapeutic Conditions 2021 & 2028 (%)
8.3 Gaucher's Disease
8.3.1 Overview
8.3.2 Gaucher's Disease - Market Revenue and Forecast to 2028 (US$ Million)
8.4 Fabry's Disease
8.4.1 Overview
8.4.2 Fabry's Disease - Market Revenue and Forecast to 2028 (US$ Million)
8.5 Mucopolysaccharidosis (MPS)
8.5.1 Overview
8.5.2 MPS - Market Revenue and Forecast to 2028 (US$ Million)
8.6 Pompe's Disease
8.6.1 Overview
8.6.2 Pompe's Disease - Market Revenue and Forecast to 2028 (US$ Million)
8.7 SCID
8.7.1 Overview
8.7.2 SCID - Market Revenue and Forecast to 2028 (US$ Million)
8.8 Other Therapeutic Conditions
8.8.1 Overview
8.8.2 Other Therapeutic Conditions - Market Revenue and Forecast to 2028 (US$ Million)
9. Europe Enzyme Replacement Therapy Market Analysis and Forecasts To 2028 – By Route of Administration
9.1 Overview
9.2 Europe Enzyme Replacement Therapy Market, By Route of Administration 2021 & 2028 (%)
9.3 Parenteral
9.3.1 Overview
9.3.2 Parenteral - Market Revenue and Forecast to 2028 (US$ Million)
9.4 Oral
9.4.1 Overview
9.4.2 Oral - Market Revenue and Forecast to 2028 (US$ Million)
10. Europe Enzyme Replacement Therapy Market Analysis– By End User
10.1 Overview
10.2 Europe Enzyme Replacement Therapy Market, By End User 2021 & 2028 (%)
10.3 Hospitals
10.3.1 Overview
10.3.2 Hospitals - Market Revenue and Forecasts To 2028 (US$ Million)
10.4 Infusion Centers
10.4.1 Overview
10.4.2 Infusion Centers - Market Revenue and Forecasts To 2028 (US$ Million)
10.5 Others
10.5.1 Overview
10.5.2 Others - Market Revenue and Forecasts To 2028 (US$ Million)
11. Europe Enzyme Replacement Therapy Market Revenue and Forecasts to 2028 – Country Analysis
11.1 Europe: Enzyme Replacement Therapy Market
11.1.1 Overview
11.1.3 Europe: Enzyme Replacement Therapy Market, by Country, 2021 & 2028 (%)
11.1.3.1 Germany: Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)
11.1.3.1.1 Overview
11.1.3.1.2 Germany: Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)
11.1.3.1.3 Germany: Enzyme Replacement Therapy Market, by Enzyme Type, 2019-2028 (US$ Million)
11.1.3.1.4 Germany: Enzyme Replacement Therapy Market, by Therapeutic Conditions, 2019-2028 (US$ Million)
11.1.3.1.5 Germany: Enzyme Replacement Therapy Market, by Route of Administration, 2019-2028 (US$ Million)
11.1.3.1.6 Germany: Enzyme Replacement Therapy Market, by End User, 2019-2028 (US$ Million)
11.1.3.2 UK: Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)
11.1.3.2.1 Overview
11.1.3.2.2 UK: Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)
11.1.3.2.3 UK: Enzyme Replacement Therapy Market, by Enzyme Type, 2019-2028 (US$ Million)
11.1.3.2.4 UK: Enzyme Replacement Therapy Market, by Therapeutic Conditions, 2019-2028 (US$ Million)
11.1.3.2.5 UK: Enzyme Replacement Therapy Market, by Route of Administration, 2019-2028 (US$ Million)
11.1.3.2.6 UK: Enzyme Replacement Therapy Market, by End User, 2019-2028 (US$ Million)
11.1.3.3 France: Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)
11.1.3.3.1 Overview
11.1.3.3.2 France: Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)
11.1.3.3.3 France: Enzyme Replacement Therapy Market, by Enzyme Type, 2019-2028 (US$ Million)
11.1.3.3.4 France: Enzyme Replacement Therapy Market, by Therapeutic Conditions, 2019-2028 (US$ Million)
11.1.3.3.5 France: Enzyme Replacement Therapy Market, by Route of Administration, 2019-2028 (US$ Million)
11.1.3.3.6 France: Enzyme Replacement Therapy Market, by End User, 2019-2028 (US$ Million)
11.1.3.4 Italy: Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)
11.1.3.4.1 Overview
11.1.3.4.2 Italy: Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)
11.1.3.4.3 Italy: Enzyme Replacement Therapy Market, by Enzyme Type, 2019-2028 (US$ Million)
11.1.3.4.4 Italy: Enzyme Replacem4ent Therapy Market, by Therapeutic Conditions, 2019-2028 (US$ Million)
11.1.3.4.5 Italy: Enzyme Replacement Therapy Market, by Route of Administration, 2019-2028 (US$ Million)
11.1.3.4.6 Italy: Enzyme Replacement Therapy Market, by End User, 2019-2028 (US$ Million)
11.1.3.5 Spain: Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)
11.1.3.5.1 Overview
11.1.3.5.2 Spain: Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)
11.1.3.5.3 Spain: Enzyme Replacement Therapy Market, by Enzyme Type, 2019-2028 (US$ Million)
11.1.3.5.4 Spain: Enzyme Replacement Therapy Market, by Therapeutic Conditions, 2019-2028 (US$ Million)
11.1.3.5.5 Spain: Enzyme Replacement Therapy Market, by Route of Administration, 2019-2028 (US$ Million)
11.1.3.5.6 Spain: Enzyme Replacement Therapy Market, by End User, 2019-2028 (US$ Million)
11.1.3.6 Rest of Europe: Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)
11.1.3.6.1 Overview
11.1.3.6.2 Rest of Europe: Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)
11.1.3.6.3 Rest of Europe: Enzyme Replacement Therapy Market, by Enzyme Type, 2019-2028 (US$ Million)
11.1.3.6.4 Rest of Europe: Enzyme Replacement Therapy Market, by Therapeutic Conditions, 2019-2028 (US$ Million)
11.1.3.6.5 Rest of Europe: Enzyme Replacement Therapy Market, by Route of Administration, 2019-2028 (US$ Million)
11.1.3.6.6 Rest of Europe: Enzyme Replacement Therapy Market, by End User, 2019-2028 (US$ Million)
12. Europe Enzyme Replacement Therapy Market–Industry Landscape
12.1 Overview
12.2 Inorganic Growth Strategies
12.2.1 Overview
12.3 Organic Growth Strategies
12.3.1 Overview
13. Company Profiles
13.1 Sanofi
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 BioMarin Pharmaceutical Inc.
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Takeda Pharmaceutical Company Limited
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 AbbVie Inc.
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Janssen Pharmaceuticals (Johnson & Johnson Services, Inc.)
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Alexion Pharmaceuticals, Inc. (AstraZeneca)
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 WOT Analysis
13.6.6 Key Developments
13.7 Amicus Therapeutics
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Recordati S.p.A.
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 CHIESI Farmaceutici S.p.A.
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Pfizer Inc.
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms
LIST OF TABLES
Table 1. Germany Enzyme Replacement Therapy Market, by Enzyme Type – Revenue and Forecast to 2028 (US$ Million)
Table 2. Germany Enzyme Replacement Therapy Market, by Therapeutic Conditions – Revenue and Forecast to 2028 (USD Million)
Table 3. Germany Enzyme Replacement Therapy Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 4. Germany Enzyme Replacement Therapy Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 5. UK Enzyme Replacement Therapy Market, by Enzyme Type – Revenue and Forecast to 2028 (US$ Million)
Table 6. UK Enzyme Replacement Therapy Market, by Therapeutic Conditions – Revenue and Forecast to 2028 (USD Million)
Table 7. UK Enzyme Replacement Therapy Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 8. UK Enzyme Replacement Therapy Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 9. France Enzyme Replacement Therapy Market, by Enzyme Type – Revenue and Forecast to 2028 (US$ Million)
Table 10. France Enzyme Replacement Therapy Market, by Therapeutic Conditions – Revenue and Forecast to 2028 (USD Million)
Table 11. France Enzyme Replacement Therapy Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 12. France Enzyme Replacement Therapy Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 13. Italy Enzyme Replacement Therapy Market, by Enzyme Type – Revenue and Forecast to 2028 (US$ Million)
Table 14. Italy Enzyme Replacement Therapy Market, by Therapeutic Conditions – Revenue and Forecast to 2028 (USD Million)
Table 15. Italy Enzyme Replacement Therapy Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 16. Italy Enzyme Replacement Therapy Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 17. Spain Enzyme Replacement Therapy Market, by Enzyme Type – Revenue and Forecast to 2028 (US$ Million)
Table 18. Spain Enzyme Replacement Therapy Market, by Therapeutic Conditions – Revenue and Forecast to 2028 (USD Million)
Table 19. Spain Enzyme Replacement Therapy Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 20. Spain Enzyme Replacement Therapy Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 21. Rest of Europe Enzyme Replacement Therapy Market, by Enzyme Type – Revenue and Forecast to 2028 (US$ Million)
Table 22. Rest of Europe Enzyme Replacement Therapy Market, by Therapeutic Conditions – Revenue and Forecast to 2028 (USD Million)
Table 23. Rest of Europe Enzyme Replacement Therapy Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 24. Rest of Europe Enzyme Replacement Therapy Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 25. Recent Inorganic Growth Strategies in the Enzyme Replacement Therapy Market
Table 26. Recent Organic Growth Strategies in the Enzyme Replacement Therapy Market
Table 27. Glossary of Terms
LIST OF FIGURES
Figure 1. Europe Enzyme Replacement Therapy Market Segmentation
Figure 2. Europe Enzyme Replacement Therapy Market Segmentation, By Country
Figure 3. Europe Enzyme Replacement Therapy Market Overview
Figure 4. Europe Enzyme Replacement Therapy Market, By Enzyme Type
Figure 5. Europe Enzyme Replacement Therapy Market, By Country
Figure 7. Europe: PEST Analysis
Figure 8. Expert Opinion
Figure 9. Europe Impact Analysis
Figure 10. Europe Enzyme Replacement Therapy Market– Revenue Forecast and Analysis – 2020- 2028
Figure 11. Europe Enzyme Replacement Therapy Market, by Enzyme Type 2021 & 2028 (%)
Figure 12. Europe Alglucosidase Alfa Revenue and Forecasts to 2028 (US$ Million)
Figure 13. Europe Agalsidase Beta - Revenue and Forecasts to 2028 (US$ Million)
Figure 14. Europe Imiglucerase - Revenue and Forecasts to 2028 (US$ Million)
Figure 15. Europe Idursulfase - Revenue and Forecasts to 2028 (US$ Million)
Figure 16. Europe Galsulfase - Revenue and Forecasts to 2028 (US$ Million)
Figure 17. Europe Velaglucerase Alfa - Revenue and Forecasts to 2028 (US$ Million)
Figure 18. Europe Other Enzymes - Revenue and Forecasts to 2028 (US$ Million)
Figure 19. Europe Enzyme Replacement Therapy Market, by Therapeutic Conditions 2021 & 2028 (%)
Figure 20. Europe Gaucher's Disease - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 21. Europe Fabry's Disease - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 22. Europe MPS - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 23. Europe Pompe's Disease - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 24. Europe SCID - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 25. Europe Other Therapeutic Conditions - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 26. Europe Enzyme Replacement Therapy Market, by Route of Administration 2021 & 2028 (%)
Figure 27. Europe Parenteral - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 28. Europe Oral - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 29. Europe Enzyme Replacement Therapy Market, by End User 2021 & 2028 (%)
Figure 30. Europe Hospitals - Market Revenue and Forecasts To 2028 (US$ Million)
Figure 31. Europe Infusion Centers - Market Revenue and Forecasts To 2028 (US$ Million)
Figure 32. Europe Others- Market Revenue and Forecasts To 2028 (US$ Million)
Figure 33. Europe: Enzyme Replacement Therapy Market, by Key Country – Revenue (2021) (US$ Million)
Figure 34. Europe: Enzyme Replacement Therapy Market, by Country, 2021 & 2028 (%)
Figure 35. Germany: Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)
Figure 36. UK: Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)
Figure 37. France: Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)
Figure 38. Italy: Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)
Figure 39. Spain: Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)
Figure 40. Rest of Europe: Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)
- Sanofi.
- BioMarine Pharmaceutical Inc.
- Takeda Pharmaceutical Company Limited.
- AbbVie Inc.
- Janssen Pharmaceutical ( Johnson & Johnson Services,Inc.).
- Alexion Pharmaceutical, Inc.(AstaZeneca).
- Amicus Therapeutics.
- Recordati S.p.A.
- CHIESI farmaceutici S.p.A.
- Pfizer Inc.
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe enzyme replacement therapy market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the Europe enzyme replacement therapy market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the enzyme replacement therapy market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution